

ECOSOC

Special Event on Philanthropy
and the Public Health Agenda
February 23, 2009



Raising the profile of the
neglected tropical diseases

Bernard Pécoul, MD/MPH
Executive Director, DNDi

DNDi

Drugs for Neglected Diseases *initiative*

Respond to the Needs of Patients Suffering from Neglected Diseases



Malaria



Visceral Leishmaniasis (VL)




Sleeping Sickness (HAT)



Chagas Disease

Only 21 New Drugs Developed for Neglected Diseases (1975-2004)



Total: 1,556


Tropical diseases and tuberculosis account for **12%** of the global disease burden but only **1.3%** of new drugs developed.

Source: Chirac P, Torreele E. *Lancet*. 2006 May 12; 1560-1561.

Neglected Diseases: Current Treatment Limitations



Melarsoprol




Eflornithine

- Ineffective (resistance)
- Toxic
- Expensive
- Painful when delivered
- Difficult to use
- Not registered in endemic regions
- Restricted by patents

We Need Safe, Effective, Easy to Use Drugs


DNDi's Virtual Model Attracting Partnerships across the Globe



128 Partners Worldwide
(45% public /
55% private)

7 Founding Partners
(4 from endemic
countries)

A robust portfolio to deliver 6-8 treatments by 2014



3 Products already available

Available

2007

ASAQ (Malaria)
Fixed-Dose
Artesunate/
Amodiaquine



Partners

sanofi-aventis
(France)

2008

ASMQ (Malaria)
Fixed-Dose
Artesunate/
Mefloquine



Farmanguinhos
(Brazil)
Cipla
(India)

2009

NECT
Nifurtimox -
Eflornithine
Co-Administration
(HAT)




**National Control
Programs**
MSF
WHO

- Easy to Use
- Affordable
- Field-Adapted
- Non-Patented

Funding Diversity

\$150M of \$350M Secured (2004-2014)

Projected Commitments



Independence through diversified sources of funding (50% from public sector & 50% from private sector)

Private Donors

- Bill & Melinda Gates Foundation
- MSF
- Other Private Foundations

Public Donors

- European Union
- France
- Germany
- Italy
- Netherlands
- Spain
- Switzerland
- UK
- USA - NIH

Ensuring Sustainability Via Public Leadership & Private Contributions

- Establish agenda and R&D priorities
(implementation of WHO's Global Action Plan)
- Significantly invest with sustainable funding
- Access to knowledge and new science for R&D
- Allow rapid approval & delivery and devise new IP management policies to encourage needs-driven R&D
- Transfer technology and strengthen research capacities in developing countries



**By working in a creative way,
we can bring together innovation
to neglected patients!**



www.dndi.org

DNDi

Drugs for Neglected Diseases *initiative*

DNDi

Drugs for Neglected Diseases *initiative*